[Anatom1]

Спасибо за информацию. Но опять же в приведённой мною статье European Medicines Agency

Prescribers are advised that the indication for oral tolperisone has been restricted to the treatment of post-stroke spasticity in adults. Doctors should stop prescribing tolperisone for any other indication.

Это чёткое указание на то, что врачи должны прекратить применение толперизона при других патологиях ( кроме постинсультной спастики)

[Ссылки доступны только зарегистрированным пользователям ]

The Committee therefore considered that the benefit-risk balance of tolperisone-containing oral
formulations under normal conditions of use:
o Is positive for symptomatic treatment of post-stroke spasticity in adults.
o Is not positive for treatment of muscular hypertonicity and muscle spasms associated
with locomotor disease.
o Is not positive for rehabilitation after orthopaedic and trauma surgery.
o Is not positive for treatment of obliterative vascular diseases as well as syndromes due
to impaired vascular innervation.
o Is not positive for Little’s disease and other encephalopaties accompanied by dystonia.
• The Committee also concluded that, in the absence of relevant data to support the efficacy in
the dosing recommendations approved, the potential benefit of tolperisone-containing
parenteral formulations is outweighed by the identified risk of hypersensitivity.

Я относительно широко применяю указанный препарат, но ведь European Medicines Agency не самая последняя организация...
Вот и спрашиваю мнение коллег.